← SynDRA
LY-2886721
SynDRA canonical compound SYN0037408 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | BACE1 |
|---|
| Mechanism of action | beta-secretase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
Cross-references
Synonyms
- LY2886721
- LY 2886721
- UNII-2CQ62IWB67
- 2CQ62IWB67
- N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide
- CHEMBL2396989
- N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide
- n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide
- NIDRNVHMMDAAIK-YPMLDQLKSA-N
- MLS006011070
- SCHEMBL966802
- GTPL6475
- RefChem:154547
- DTXCID9077608
- MFCD22124078
- C18H16F2N4O2S
- orb1301111
- SCHEMBL30477100
- EX-A029
- GLXC-05140
- HMS3884J09
- BDBM50012647
- s2156
- AKOS027422646
- LY 2886721 - Bio-X trade mark
- CCG-268530
- CS-0458
- NCGC00346506-04
- NCGC00346506-07
- AC-33097
- AS-56127
- BL300094
- FL103714
- HY-13240
- SMR004702860
- LY2886721?
- NS00072934
- T6058
- 3YS
Look up LY-2886721 in the interactive SynDRA portal →